Clinical Data Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial PharmaTimesResponders achieved weight loss and improvements in physical functionMetabolic & GLP-1Read full story pharminent May 13, 2026 (Last updated: May 21, 2026) PharmaTimes Responders achieved weight loss and improvements in physical function Metabolic & GLP-1 Read full story Post navigation Previous: UAE approves AstraZeneca’s Baxfendy for hypertensionNext: Clock starts ticking on UK’s single patient record plan Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026